Wells Fargo analyst Larry Biegelsen maintained a Hold rating on Axonics Modulation Technologies (AXNX – Research Report) today and set a price target of $71.00. The company’s shares opened today at $66.68.
Biegelsen covers the Healthcare sector, focusing on stocks such as Abbott Labs, Medtronic, and Bausch + Lomb Corporation. According to TipRanks, Biegelsen has an average return of 10.0% and a 56.85% success rate on recommended stocks.
Axonics Modulation Technologies has an analyst consensus of Hold, with a price target consensus of $71.00, representing a 6.48% upside. In a report released on April 15, RBC Capital also maintained a Hold rating on the stock with a $71.00 price target.
Based on Axonics Modulation Technologies’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $109.74 million and a net profit of $6.53 million. In comparison, last year the company earned a revenue of $85.92 million and had a net profit of $697 thousand
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Axonics Modulation Technologies (AXNX) Company Description:
Axonics Modulation Technologies, Inc. operates as a medical technology company, which engages in the design, development, and commercialization of sacral neuromodulation solutions. The firm focuses on the treatment of patients with overactive bladder (OAB), fecal incontinence (FI), and urinary retention (UR). It offers rechargeable SNM system, which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, FI, and UR. The company was founded by Guang Qiang Jiang, Danny L. Dearen, Timothy Deer, and Michael V. Williamson in March 2012 and is headquartered in Irvine, CA.
Read More on AXNX:
